ArticleACS omega2025
Peptide Family Promotes Brain Cell Rejuvenation and Improved Cognition through Peripheral Delivery.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Redirecting microglia phenotype via inhibition of NFAT1 ameliorates deficits in mouse model of synucleinopathies.Experimental & molecular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ligands targeting folate receptor α (FRα), a protein predominantly expressed in neural cells, have the potential to reprogram (rejuvenate) brain cells and enhance cognitive function in aged mice. In this study, we present a family of FRα-binding peptides identified through AlphaFold modeling. These peptides induce a structural change in the receptor upon binding, which facilitates its internalization and transport to the cell nucleus. Once in the nucleus, FRα functions as a transcription factor, promoting the expression of genes associated with a youthful phenotype and improved cognition. Notably, these peptides demonstrate permeability across the blood-brain barrier, enabling their administration not only through intracranial injection but also via peripheral delivery methods such as intraperitoneal injection or gastric gavage. This property enhances their potential for use in future therapeutic applications.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.